150 related articles for article (PubMed ID: 37937506)
1. Targeting TP53 disruption in chronic lymphocytic leukemia: Current strategies and future directions.
Molica S; Tam C; Allsup D; Polliack A
Hematol Oncol; 2024 Jan; 42(1):e3238. PubMed ID: 37937506
[TBL] [Abstract][Full Text] [Related]
2. ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells.
Kwok M; Davies N; Agathanggelou A; Smith E; Oldreive C; Petermann E; Stewart G; Brown J; Lau A; Pratt G; Parry H; Taylor M; Moss P; Hillmen P; Stankovic T
Blood; 2016 Feb; 127(5):582-95. PubMed ID: 26563132
[TBL] [Abstract][Full Text] [Related]
3. Targeting p53 in chronic lymphocytic leukemia.
Moia R; Boggione P; Mahmoud AM; Kodipad AA; Adhinaveni R; Sagiraju S; Patriarca A; Gaidano G
Expert Opin Ther Targets; 2020 Dec; 24(12):1239-1250. PubMed ID: 33016796
[TBL] [Abstract][Full Text] [Related]
4. The Ongoing Unmet Needs in Chronic Lymphocytic Leukemia: TP53 Disruption, Richter, and Beyond.
Ding W
Hematol Oncol Clin North Am; 2021 Aug; 35(4):739-759. PubMed ID: 34174984
[TBL] [Abstract][Full Text] [Related]
5. PRIMA-1
Jaskova Z; Pavlova S; Malcikova J; Brychtova Y; Trbusek M
Leuk Res; 2020 Feb; 89():106288. PubMed ID: 31924585
[TBL] [Abstract][Full Text] [Related]
6. Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemia.
Knittel G; Rehkämper T; Korovkina D; Liedgens P; Fritz C; Torgovnick A; Al-Baldawi Y; Al-Maarri M; Cun Y; Fedorchenko O; Riabinska A; Beleggia F; Nguyen PH; Wunderlich FT; Ortmann M; Montesinos-Rongen M; Tausch E; Stilgenbauer S; P Frenzel L; Herling M; Herling C; Bahlo J; Hallek M; Peifer M; Buettner R; Persigehl T; Reinhardt HC
Nat Commun; 2017 Jul; 8(1):153. PubMed ID: 28751718
[TBL] [Abstract][Full Text] [Related]
7. USP7 inhibition alters homologous recombination repair and targets CLL cells independently of ATM/p53 functional status.
Agathanggelou A; Smith E; Davies NJ; Kwok M; Zlatanou A; Oldreive CE; Mao J; Da Costa D; Yadollahi S; Perry T; Kearns P; Skowronska A; Yates E; Parry H; Hillmen P; Reverdy C; Delansorne R; Paneesha S; Pratt G; Moss P; Taylor AMR; Stewart GS; Stankovic T
Blood; 2017 Jul; 130(2):156-166. PubMed ID: 28495793
[TBL] [Abstract][Full Text] [Related]
8. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.
Zenz T; Häbe S; Denzel T; Mohr J; Winkler D; Bühler A; Sarno A; Groner S; Mertens D; Busch R; Hallek M; Döhner H; Stilgenbauer S
Blood; 2009 Sep; 114(13):2589-97. PubMed ID: 19643983
[TBL] [Abstract][Full Text] [Related]
9. Potential of BCL2 as a target for chronic lymphocytic leukemia treatment.
Moia R; Diop F; Favini C; Kodipad AA; Gaidano G
Expert Rev Hematol; 2018 May; 11(5):391-402. PubMed ID: 29561706
[TBL] [Abstract][Full Text] [Related]
10. Assessment of p53 and ATM functionality in chronic lymphocytic leukemia by multiplex ligation-dependent probe amplification.
te Raa GD; Moerland PD; Leeksma AC; Derks IA; Yigittop H; Laddach N; Loden-van Straaten M; Navrkalova V; Trbusek M; Luijks DM; Zenz T; Skowronska A; Hoogendoorn M; Stankovic T; van Oers MH; Eldering E; Kater AP
Cell Death Dis; 2015 Aug; 6(8):e1852. PubMed ID: 26247737
[TBL] [Abstract][Full Text] [Related]
11. Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells.
Boudny M; Zemanova J; Khirsariya P; Borsky M; Verner J; Cerna J; Oltova A; Seda V; Mraz M; Jaros J; Jaskova Z; Spunarova M; Brychtova Y; Soucek K; Drapela S; Kasparkova M; Mayer J; Paruch K; Trbusek M
Haematologica; 2019 Dec; 104(12):2443-2455. PubMed ID: 30975914
[TBL] [Abstract][Full Text] [Related]
12. Targeting the Ataxia Telangiectasia Mutated-null phenotype in chronic lymphocytic leukemia with pro-oxidants.
Agathanggelou A; Weston VJ; Perry T; Davies NJ; Skowronska A; Payne DT; Fossey JS; Oldreive CE; Wei W; Pratt G; Parry H; Oscier D; Coles SJ; Hole PS; Darley RL; McMahon M; Hayes JD; Moss P; Stewart GS; Taylor AM; Stankovic T
Haematologica; 2015 Aug; 100(8):1076-85. PubMed ID: 25840602
[TBL] [Abstract][Full Text] [Related]
13.
Aptullahoglu E; Wallis JP; Marr H; Marshall S; Bown N; Willmore E; Lunec J
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511096
[TBL] [Abstract][Full Text] [Related]
14. AICAR induces apoptosis independently of AMPK and p53 through up-regulation of the BH3-only proteins BIM and NOXA in chronic lymphocytic leukemia cells.
Santidrián AF; González-Gironès DM; Iglesias-Serret D; Coll-Mulet L; Cosialls AM; de Frias M; Campàs C; González-Barca E; Alonso E; Labi V; Viollet B; Benito A; Pons G; Villunger A; Gil J
Blood; 2010 Oct; 116(16):3023-32. PubMed ID: 20664053
[TBL] [Abstract][Full Text] [Related]
15. A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in TP53.
Shindiapina P; Brown JR; Danilov AV
Br J Haematol; 2014 Oct; 167(2):149-61. PubMed ID: 25040077
[TBL] [Abstract][Full Text] [Related]
16. An update on: molecular genetics of high-risk chronic lymphocytic leukemia.
Moia R; Patriarca A; Deambrogi C; Rasi S; Favini C; Kodipad AA; Schipani M; Gaidano G
Expert Rev Hematol; 2020 Feb; 13(2):109-116. PubMed ID: 31774349
[No Abstract] [Full Text] [Related]
17. Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation.
Buccheri V; Barreto WG; Fogliatto LM; Capra M; Marchiani M; Rocha V
Ann Hematol; 2018 Dec; 97(12):2269-2278. PubMed ID: 30315344
[TBL] [Abstract][Full Text] [Related]
18. Richter transformation of chronic lymphocytic leukemia in the era of novel agents.
Wang Y; Ding W
Clin Adv Hematol Oncol; 2020 Jun; 18(6):348-357. PubMed ID: 32649656
[TBL] [Abstract][Full Text] [Related]
19. The potential anticancer agent PK11195 induces apoptosis irrespective of p53 and ATM status in chronic lymphocytic leukemia cells.
Santidrián AF; Cosialls AM; Coll-Mulet L; Iglesias-Serret D; de Frias M; González-Gironès DM; Campàs C; Domingo A; Pons G; Gil J
Haematologica; 2007 Dec; 92(12):1631-8. PubMed ID: 18055986
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic inhibition of USP7-PTEN network in chronic lymphocytic leukemia: a strategy to overcome TP53 mutated/deleted clones.
Carrà G; Panuzzo C; Torti D; Parvis G; Crivellaro S; Familiari U; Volante M; Morena D; Lingua MF; Brancaccio M; Guerrasio A; Pandolfi PP; Saglio G; Taulli R; Morotti A
Oncotarget; 2017 May; 8(22):35508-35522. PubMed ID: 28418900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
